TargetMol

Rostaporfin

Product Code:
 
TAR-T34393
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T34393-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Rostaporfin (also known as REM-001, tin ethyl etiopurpurin, Sn(IV) etiopurpurin, Purlytin, SnET2), is a synthetic purpurin with photosensitizing activity. Rostaporfin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects.
CAS:
284041-10-7
Formula:
C37H42Cl2N4O2Sn
Molecular Weight:
764.37
Purity:
0.98
SMILES:
CCC1=C(C2=CC3=C(C(=C4[N-]3[Sn+4]56(N2=C1C=C7[N-]5C8=C(C=C([C@]8([C@@H]7C)CC)C(=O)OCC)C9=N6C(=C4)C(=C9C)CC)([Cl-])[Cl-])C)CC)C

References

Jankun J, Keck RW, Skrzypczak-Jankun E, Lilge L, Selman SH. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. BJU Int. 2005 Jun;95(9):1237-44. PubMed PMID: 15892808. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C, Dimitrakos SA 2nd, Korobelnik JF, Larsen M, Monés J, Pauleikhoff D, Pournaras CJ, Staurenghi G, Virgili G, Wolf S. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol. 2006 Sep;90(9):1188-96. PubMed PMID: 16929063; PubMed Central PMCID: PMC1857411. Skrzypczak-Jankun E, Borbulevych OY, Melillo A, Keck R, Soriano-Garcia M, Aniola J, Niedre M, Lilge L, Selman SH, Jankun J. Aspirin blocks binding of photosensitizer SnET2 into human serum albumin: implications for photodynamic therapy. Int J Mol Med. 2005 May;15(5):777-83. PubMed PMID: 15806298. Sivaprasad S, Hykin P. The role of photodynamic therapy in ophthalmology. Br J Hosp Med (Lond). 2006 Dec;67(12):647-50. Review. PubMed PMID: 17328448.